La traducción aún no está lista. Se muestra el artículo original.
Novo Nordisk reported third quarter 2026 sales of DKK 79,195 million and net income of DKK 16,740 million, raised its full year sales and profit outlook, and cited strong demand for GLP 1 obesity and diabetes treatments, especially the Wegovy pill. The earnings update showed oral Wegovy rapidly becoming a central product, with management leaning on this momentum while also planning meaningful US list price cuts for Wegovy and Ozempic from January 2027. We will now look at how Novo Nordisk's stronger outlook, anchored in Wegovy pill demand, affects the broader investment narrative. Scan how Novo Nordisk's GLP 1 momentum compares with other potential breakouts in obesity and metabolic care by reviewing the hand picked 126 healthcare AI stocks list.
Mostramos la idea principal publicamente. Crea una cuenta gratis para seguir leyendo el articulo completo, guardarlo, comentarlo y conectarlo con contexto de mercados y OSINT.